Pages that link to "Q35024744"

The following pages link to Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer (Q35024744):

Displaying 14 items.

• A laboratory prognostic index model for patients with advanced non-small cell lung cancer (Q28542513) (← links)
• Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo (Q34103311) (← links)
• Smoking and Prognostic Factors in an Observational Setting in Patients with Advanced Non-Small Cell Lung Carcinoma (Q34487100) (← links)
• Erlotinib in non-small cell lung cancer: a review (Q36161290) (← links)
• Current status of cetuximab for the treatment of patients with solid tumors. (Q36364973) (← links)
• The surgical management of lung cancer (Q36391408) (← links)
• How will lung cancer be treated in the future? (Q36429550) (← links)
• Therapeutic resistance in lung cancer (Q36609767) (← links)
• Implications of EGFR PharmDx kit for cetuximab eligibility (Q37118974) (← links)
• Epothilones in Development for Non–Small-Cell Lung Cancer: Novel Anti-Tubulin Agents With the Potential to Overcome Taxane Resistance (Q37963559) (← links)
• Effects of in vitro exposure of Echinococcus multilocularis metacestodes to cytostatic drugs on in vivo growth and proliferation of the parasite (Q39091340) (← links)
• Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy (Q42732266) (← links)
• Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase (Q48099410) (← links)
• SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. (Q55497899) (← links)